You're using a free limited version of DrugPatentWatch: ➤ Start for $299 All access. No Commitment.

Last Updated: December 12, 2025

Details for New Drug Application (NDA): 022145

✉ Email this page to a colleague

NDA 022145 describes ISENTRESS HD, which is a drug marketed by Msd Sub Merck and is included in one NDA. It is available from five suppliers. There are four patents protecting this drug. Additional details are available on the ISENTRESS HD profile page.

The generic ingredient in ISENTRESS HD is raltegravir potassium. There are five drug master file entries for this compound. Five suppliers are listed for this compound. Additional details are available on the raltegravir potassium profile page.

Summary for 022145

Tradename:	ISENTRESS HD
Applicant:	Msd Sub Merck
Ingredient:	raltegravir potassium
Patents:	5

Pharmacology for NDA: 022145

Mechanism of Action	HIV Integrase Inhibitors

Medical Subject Heading (MeSH) Categories for 022145

Anti-HIV Agents
HIV Integrase Inhibitors

Suppliers and Packaging for NDA: 022145

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
ISENTRESS	raltegravir potassium	TABLET;ORAL	022145	NDA	Merck Sharp & Dohme LLC	0006-0227	0006-0227-61	60 TABLET, FILM COATED in 1 BOTTLE (0006-0227-61)
ISENTRESS	raltegravir potassium	TABLET;ORAL	022145	NDA	Merck Sharp & Dohme LLC	0006-3080	0006-3080-01	60 TABLET, FILM COATED in 1 BOTTLE (0006-3080-01)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	EQ 400MG BASE
Approval Date:	Oct 12, 2007	TE:		RLD:	Yes
Patent:	⤷ Get Started Free	Patent Expiration:	Sep 11, 2029	Product Flag?		Substance Flag?		Delist Request?	Y
Patent:	⤷ Get Started Free	Patent Expiration:	Jun 2, 2030	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HIV INFECTION
Patent:	⤷ Get Started Free	Patent Expiration:	Jan 28, 2028	Product Flag?	Y	Substance Flag?	Y	Delist Request?
Patented Use:	TREATMENT OF HIV INFECTION

Expired US Patents for NDA 022145

Subscribe to access the full database, or Get Started Free
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	⤷ Get Started Free	⤷ Get Started Free
Msd Sub Merck	ISENTRESS	raltegravir potassium	TABLET;ORAL	022145-001	Oct 12, 2007	⤷ Get Started Free	⤷ Get Started Free
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	⤷ Get Started Free	⤷ Get Started Free
Msd Sub Merck	ISENTRESS HD	raltegravir potassium	TABLET;ORAL	022145-002	May 26, 2017	⤷ Get Started Free	⤷ Get Started Free
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Complete Access Available with Subscription

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.